Pharma channel feed

Bio­phar­ma lead­ers con­demn mob vi­o­lence on Capi­tol Hill, look­ing to close Trump's chaot­ic chap­ter in Amer­i­can his­to­ry

5 years ago

New year, new me: Pfiz­er aban­dons icon­ic 'blue pil­l' lo­go in fa­vor of sleek­er — if more am­bigu­ous — new de­sign

5 years ago

So why is Alex­ion pay­ing $100M for a PRV as As­traZeneca lines up their $39B buy­out?

5 years ago
Deals

Re­call re­port: Nos­trum ex­pands re­call of di­a­betes drug met­formin af­ter car­cino­gen con­cerns

5 years ago
FDA+

Bris­tol My­ers Squibb walks on Op­di­vo's FDA nod for small-cell lung can­cer af­ter mid­dling OS da­ta could­n't back ap­proval

5 years ago
FDA+

EU reg­u­la­tor says As­traZeneca ap­proval not im­mi­nent, even as Pas­cal So­ri­ot teas­es stronger da­ta

5 years ago
Coronavirus

With pipeline set­backs mount­ing, Unit­ed snares pri­or­i­ty vouch­er for in­haled for­mu­la­tion of PAH med Ty­va­so

5 years ago
FDA+

A fed­er­al judge blocks Don­ald Trump's 'most fa­vored na­tion' drug pric­ing plan as the lease runs out on the White House

5 years ago

Af­ter mul­ti­ple set­backs, Bris­tol My­ers scut­tles Op­di­vo pro­gram for brain tu­mor pa­tients af­ter fail­ing to pro­long lives

5 years ago
R&D

Twist Bio­science plots its 'fac­to­ry of the fu­ture' in Ore­gon, seeks to ex­pand syn­thet­ic DNA client base

5 years ago
Manufacturing

Mi­nor­i­ty in­vestor Wa­ter­Mill suc­ceeds in ac­tivist at­tack of Zio­pharm, win­ning two board seats and re­moval of chair­man

5 years ago

Glax­o­SmithK­line's Benlysta earns first FDA ap­proval for lu­pus nephri­tis as com­peti­tors wait in the wings

5 years ago
FDA+

Macro­Gen­ics scores first FDA ap­proval with breast can­cer med Mar­gen­za in third-line pa­tients

5 years ago
FDA+

No­var­tis sets eyes on new­ly-ac­quired Alex­ion with break­through tag for rare dis­ease hope­ful ip­ta­co­pan

5 years ago
FDA+

No­var­tis earns ad­com­m's vote of sup­port in come­back FDA re­view for En­tresto in sought-af­ter heart fail­ure pa­tients

5 years ago
FDA+

Bob Nelsen ex­its board and pres­i­dent steps down at Uni­ty as fall­out from the an­ti-ag­ing biotech's PhII miss con­tin­ues

5 years ago
People

At­tor­neys gen­er­al ask HHS to pun­ish 340B pro­gram bilk­ers — but phar­ma claims it's fight­ing 'waste and abuse'

5 years ago

Vi­a­tris plans across-the-board cuts that could en­dan­ger 9,000 work­ers, 15 plants in post-merg­er re­struc­tur­ing scheme

5 years ago

De­spite flop­ping piv­otal tri­al, No­var­tis' En­tresto will face ad­comm fir­ing line for holy grail heart fail­ure pa­tients

5 years ago
FDA+

Re­call re­port: AvKARE some­how mixed its an­ti­de­pres­sant and erec­tile dys­func­tion meds; Tor­rent pulls throm­bo­cy­to­sis drug

5 years ago
FDA+

Alk­er­mes CEO Richard Pops wins over ac­tivists with a pledge to shake up the com­pa­ny and boost net in­come

5 years ago

New York law­suit again ac­cus­es Mar­tin Shkre­li of ma­nip­u­la­tion from be­hind bars

5 years ago
People

No­var­tis' CDK4/6 med Kisqali, firm­ly the sales un­der­dog against Pfiz­er's Ibrance, drops big OS da­ta

5 years ago
R&D

Ab­b­Vie chas­es its next gold­en goose in a post-Hu­mi­ra fu­ture with new ul­cer­a­tive col­i­tis da­ta for Rin­voq

5 years ago
R&D
First page Previous page 251252253254255256257 Next page Last page
A service from the Financial Times